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SUMMARY 
Recent years have witnessed a growing appreciation for the 
complexity and wide range of functions performed by lymphocytes. 
This has been particularly true for bone marrow cells (BMC) which 
have been noted to possess cells involved in hematopoiesis, lympho¬ 
poiesis, and bone metabolism. It has been repeatedly demonstrated 
that the bone marrow (BM) contains a potent suppressor cell of un¬ 
certain phenotypic identity, the physiologic significance of which 
has been only speculated upon without the benefit of decisive data. 
This thesis describes the discovery of a cell in the BM that 
reduces the suppressive activity of the bone marrow suppressor cell 
(BMSC), and outlines an integrated BM physiology based upon the 
interactions of the BMSC and its modifier cell, the contrasuppressor. 
Data is presented that shows the BMSC to be lacking all standard 
lymphocyte or macrophage cell surface markers while its supnressive 
activity differs from that of the classical T suppressor cell by its 
extraordinary range of action, its lack of a secreted soluble suppressor 
factor, and its failure to require Ly-2,3+ cells for suppressive 
activity. The contrasuppressor, which is preferentially expressed in 
neonatal mice and certain CBA substrains, is a Thy-1+ cell that is 
also extremely sensitive to a factor, probably an immunoglobulin, 
present in normal rabbit serum. 
The possible physiologic roles of these cells is demonstrated 
in experiments involving the splenic colony forming units (CFU-S) 
assay as a model of hematopoiesis and in experiments in which BMC 
were exposed to parathyroid hormone (PTH) as a stimulant of osteo- 

clastic activity. The data presented shows that maneuvers leading to 
reduced contrasuppression resulted in lower hematopoietic activity, 
as measured by the CFU-S assay, and, conversely, that the BM of anemic 
mice who had high endogenous levels of hematopoiesis also demonstrated 
elevated BM contrasuppressor activity. It was also found that BM 
suppression was markedly relieved by exposure to PTH, indicating that 
at least one PTH-specific cell was present in the contrasuppressor 
circuit. 
The work of others concerning lymphocytic involvement in experi¬ 
mental models or disease states in both hematopoiesis and bone meta¬ 
bolism is discussed in light of the data presented. Observations are 
made concerning the concept of contrasuppression as it may operate 
in a general sense as well as its use in the unique microenvironment 
of the bone marrow. The bone marrow contrasuppressor is compared to 
contrasuppressors described in other systems and its significance in 
an integrated BM physiology is speculated upon. 

INTRODUCTION 
It is said that the medieval physician Galen "considered the thymus 
to be nothing more than a pad protecting the heart from the honey 
sternum" (1). Subsequent advances in the understanding of thymic pro¬ 
duction of cellular blood products were scarce, not withstanding 
Metchinkoff's investigations in cellular immunity in the late 1800's 
(2) and a widely recognized association between thymic abnormalities 
and hypoplasia of one or more hematopoietic cell lines (1). It was 
not until 1966 that the immunologic function of lymphocytes was clearly 
shown by Gowans (3). Building upon the work of Miller, who showed in 
1961 that neonatal thymectomy resulted in numerous immunological defects 
(4), Raff, in 1969, demonstrated the thymic dependence of lymphocytes 
bearing the 9 surface antigen (5). 
It had been previously observed by Ovary and Benacerraf that the 
use of a conjugated hapten-carrier immunogen restricted the secondary 
immunologic response characteristics in a way that suggested carrier- 
specific regulation of the hapten immunogenicity (the so-called carrier 
effect) (6). When Claman, e_t al_ (7), demonstrated immunological synergism 
between thymocytes and bone marrow cells, it was quickly appreciated 
that a 2-cell model of immunocompetence would best explain these 
phenomena (8). Confirmation was presented by Raff, who demonstrated 
that a carrier-specific 9 lymphocyte, which he called a helper cell, 





The discovery of suppressor cells by Gershon in 1971 (10) was the 
first hint of true homeostatic immunoregulation at the cellular level. 
With the delineation of an uncommitted 9+, Ly-1,2,3+ pool of lympho¬ 
cytes that could generate either help or suppression depending upon the 
intermediate homeostatic requirements (11), it was not long before a 
fully integrated feedback suppression circuit was elucidated (12). 
Even before the glue had set on the suppressor circuit model, it was 
hypothesized that yet another level of control, involving the suppressor 
cell, was acting in symmetry with the regulation of helper cells. This 
concept, dubbed contrasuppression by Gershon in 1974 (13), was an 
abstraction until 1980, when it was first demonstrated experimentally 
(14,15,16). Briefly, it can be viewed as the inverse of feedback 
suppression , in which a high level of helper cell activity induces the 
creation of suppressor cells via a pool of uncommitted precursor lympho¬ 
cytes. Analogously, in the contrasuppressor circuit, a high level of 
suppressor cell activity serves to induce, via the precursor pool, 
contrasuppressor cells which subsequently act upon helper cells to render 
them resistant to suppression (16). Further discussion of this super¬ 
ficially confusing circuit can be found in Appendix I. 
Paralleling the increasingly sophisticated modeling of immune 
regulation was a growing awareness that lymphocytes could participate 
in non-immunological roles. Of particular interest has been the cellular 
milieu of the bone marrow (BM) as it anatomically provides close contact 
between cells of the lymphocytic and hematopoietic lines as well as those 
concerned with bone metabolism. While the ultrastructure of the BM 
influences differentiation among its resident cellular populations (17), 
it is also true that specific cell-to-cell interactions can alter bone 
marrow cell functions. 
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Several investigators have demonstrated a suppressor cell in 
the BM that has been termed a large lymphocyte (18), possibly a B cell 
(19,20,21) or a pre-T cell (22) which, although potently suppressive 
in an _in vitro lymphocyte culture, also was capable of non-specifically 
stimulating DNA synthesis in spleen cells (23). With the exception of 
its suppressive nature, however, none of these characterizations of the 
BM suppressor cell (BMSC) have been consistently demonstrated (20,24, 
25). 
If the BMSC is, in fact, a lymphocyte, then the question of its 
function can be raised in the context of its predominantly non-immuno- 
logic surroundings. The obvious issue of BMSC regulation of BM antibody 
production has been addressed by others (23,26) and will be discussed 
following the presentation of pertinent data. Pursuant to the larger 
concept of non-immunological roles for lymphocytes, data in the literature 
suggests that T cells, or their products, may be an important factor in 
the regulation of hematopoiesis and/or bone metabolism. Several experi¬ 
mental models of hematopoiesis have demonstrated some form of thymic 
(27,28), thymocyte (29,30,31), or T lymphocyte dependence (32,33). In 
addition, many disease states involving altered bone metabolism have 
been associated with T cells (34) or T cell products (35,36). Many 
of the experiments presented here were designed to detect just such 
interactions among the physiologic systems under examination. 
It is easily appreciated that for a dynamic system to be regulated, 
it must possess opposing regulatory mechanisms that prevent degeneration 
to either a state of uncontrolled activity or one of total shutdown. In 
the BM, where a seemingly omnipresent, non-reactive suppressor cell 
resides, it might be expected that an opposing cell, a contrasuppressor, 
_ 
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would be found that provides the BM with the flexibility to respond 
to changes in its microenvironment. Such a cell was, in fact, 
discovered. The implications of this finding will be discussed in the 




A. Adult strains: All adult mice were 6-10 weeks old and had 
been housed in the Yale mouse colony for at least 1 week after arrival 
from outside suppliers. The following strains were obtained from 
Jackson Labs: AKR, A.TH, Balb/ByJ, Balb/ByJ nude, Balb/c, C57BL6, CB.20, 
CBA/CaJ, CBA/H, CBA/J, DBA/2, NZB and SJL. C57BL6 were also obtained 
from Charles River Labs on a few occassions. The following mice were 
bred and generously donated by D. Murphy: (B6xA)F^, (B6xD2)F^, (B6/TL"*"xA)F^, 
BIO.A(IR), BIO. A(3R), B10.A(4R), B10.S, C^F and M16. J. Kemp kindly 
provided homozygous CBA/N females and (C57BL/6 x CBA/N)F^ males (defec¬ 
tive F^'s) and females (non-defective F^’s) (37). C. Janeway generously 
provided Balb/c mice that had been injected from their first feeding 
with anti-mouse immunoglobulin (Ig) (50jj1 of concentrated solution) . The 
mice were injected similarly 3 times per week thereafter until their 
sacrifice at 8 weeks of age, while control mice were injected with 
normal rabbit serum according to the same protocol. At sacrifice, the 
experimental mice were shown to have no cells with detectable surface Ig 
(38). C. Janeway also provided B6AF^ mB" mice that had been thymectomized, 
lethally irradiated, and reconstituted with anti-0 + complement treated 
syngeneic bone marrow. 
B. Neonatal strains: Pregnant female mice were obtained from 
Jackson Labs, with their offspring being used for experiments at 7 to 13 
days of age. Strains used were: C57BL6, A.TH, Balb/ByJ, and CBA/J. 
D. Murphy donated similarly aged neonates of the following strains: 




C. Bleeding: In one set of experiments, CBA/J mice were 
made anemic by alternate-day bleeding with an average blood loss of 
0.3ml, for at least 2 weeks. The hematocrit at sacrifice ranged 
between 30-35%. Normal mouse hematocrit is roughly 55%. 
D. Sacrifice: All adult mice were sacrificed by cervical 
dislocation while for neonatal mice, decapitation was required. 
II. Cell Suspensions 
A. Spleen cells (WS): Spleens were removed from the mice using 
sterile technique, then gently ground between the frosted ends of two 
sterile microscope slides to form a single-cell suspension in phosphate 
buffered saline (PBS) containing 2% fetal calf serum (FCS). After the 
cells were washed three times and all debris removed, the cells were 
diluted to a concentration estimated to be between 10^ and 2x10^ cells/ml 
and an aliquot counted by Trypan blue exclusion. 
B. Bone Marrow Cells (BMC): After disarticulation of the rear 
limbs, all overlying soft tissue was stripped from the femurs and tibias 
by sharp dissection. Using sterile technique, the metaphyses on either 
ends of the bones were removed and the marrow cavity was vigorously 
flushed with PBS with 2% FCS using a 27 gauge needle. After three 
washings, the cells were diluted and counted as for the WS. All 
nucleated BMC were included in the cell count for the BM. 
III. Cell Selection Techniques 
A. Antisera: Antisera treatments consisted of incubation of 
the cells in the antisera (diluted in Balanced Salt Solution (BSS) 
with 5% FCS according to cytotoxicity data generated within the Gershon 
- 
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lab) for 30 minutes at 4°C followed by a wash and incubation of the 
cells in complement (diluted 1:5 in BSS) for 30 minutes at 37°C. After 
at least 2 washings in PBS with 2% FCS, the cells were counted by 
Trypan blue exclusion. Antisera used were: anti-Thy-1.2 (rat hybridoma 
monoclonal antibody, a gift of J. Sprent), rabbit anti-mouse brain 
s b 
(Litton Bionetics, Kensington, MD), anti-K and anti-I-J (both gifts 
of D. Murphy). F.W. Shen very generously donated the following hetero¬ 
logous antisera: anti-Ly-1.2, anti-Ly-2.2, anti-Qa-1, anti-Qa-2/3, 
anti-N.K, and anti-Ly-5.1. Rabbit complement (RC) was either low tox 
(Cedar lane Labs) or pooled complement screened in Gershon's lab for 
low background cytotoxicity towards mouse spleen cells. Pooled guinea 
pig complement (GPC) was similarly screened before use. 
B. Positive Selection Methods: 
1. Ig plates - Plastic petri plates coated with purified 
goat anti-mouse Ig were used to selectively retain B cells, which 
possess surface Ig (slg), after the method of Wysocki and Sato (39). 
Briefly, after 70 minutes of incubation at 4°C, mouse B cells selectively 
adhere to the coated plates while the T cells that elute off with 
gentle pipeting are less than 5% contaminated with B cells. Further 
incubation of the plates at 37°C for 30 minutes allows the recovery of 
the B cells, which are less than 1% contaminated by T cells by fluores¬ 
cence. 
2. Fc plates - Selection of Fc receptor positive (FcR+) 
cells was accomplished by a modification of the method of Parish (40). 
Briefly, sheep red blood cells (SRBC’s) coated with mouse anti-SRBC 
antisera were used to cover the bottom of plastic petri dishes that 
- 
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had been coated with poly-L-lysine. Cells were incubated on these 
plates for 45 minutes at 4°C, with non-adherent cells then removed by 
gentle pipeting. Adherent cells were removed by osmotic shock and 
vigorous pipeting. 
3. Vicia Villosa (V. Villosa) - The lectin V. Villosa was 
placed on plastic petri plates and used for cell selection as described 
by Green (16). Briefly, cells were incubated on the plates for 30 
minutes at 37°C, at which time non-adherent cells were removed by gentle 
pipeting. Addition of n-acetyl-galactose amine (the specific sugar 
for the lectin) and incubation for 10 minutes at room temperature 
allowed the elution of the adherent cells. Previous studies have shown 
that macrophages do not elute from the plates, Ly-2+ cells are non¬ 
adherent, T helper cells are not adherent and roughly 50% of T 
contrasuppressor cells are in the adherent population (41). 
C. Complement Fractionation: Pooled rabbit complement (RC) 
screened for low cytotoxicity against mouse WS was used to obtain a 
solution enriched for rabbit Ig (Rig) after the method of Mishell and 
Shiigi (42). Briefly, rabbit serum was added to an equal volume of a 
saturated ammonium sulfate solution (defined at 4°C). The precipitate 
formed was centrifuged at 10,000 rpm for 10 minutes and resuspended 
in PBS. After repeating this sequence twice more, the resulting 
solution was dialyzed against PBS for 24 hours with one change of 
dialysate. The final solution was used at either a 1:10 or 1:20 dilu¬ 
tion as an antiserum. 
D. Complement Absorption: To absorb organ-specific antibodies 
from RC, equal volumes of the serum and either murine BMC or WS were 
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mixed together and incubated for 30 minutes at 4°C. After removal of 
the cells, the absorbed serum was used as a source of complement at 
a 1:3 dilution if retained complement activity was satisfactory in a 
standard cytotoxicity assay. 
F. Use of Cells After Fractionation: With all the preceding 
selection techniques, the cells of the resulting subpopulations were 
added to, for instance, an _in vitro culture in equivalent measure to 
their proportion of the unseparated cell population. For example, if 
the slg+ BMC constituted 1/3 of the starting cell population, then 1x10^ 
4“ 6 
slg BMC would be added where 3x10 unseparated BMC would be used. In 
antisera treatment, the complement control was used as the equivalence 
standard. This was done to control for the effects of RC upon BMC. 
Doing so removed a large source of artifact, although it probably 
reduced the sensitivity of the experiments involving the contrasup- 
pressor cell to some extent. 
IV. Treatment of BMC 
A. Thymopoietin (TP): TP (a gift of G. Goldstein) is a poly¬ 
peptide extract of thymus that was known to induce cell surface 9 on 
some lymphocytes (43,44). It was dissolved in RPMI 1640 with 2% FCS 
-3 7 
at concentrations between 1 and 10 jig/ral. 1x10 BMC/ml were incubated 
in the TP solution for 2 hours at 37°C, washed and counted by Trypan 
blue exclusion. 
B. Parathyroid Hormone (PTH): Powdered salmon PTH (a gift of 
R. Baron) was dissolved in RPMI 1640 with 2% FCS to a concentration 
of lug/ml (O.ljuM). 1x107 BMC/ml was incubated in the PTH solution for 
3.5 hours at 37°C, washed and counted by Trypan blue exclusion. Control 
BMC were similarly incubated in RPMI 1640 with 2% FCS. 
- 
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V. Cell Cultures 
A. Cultures: WS and BMC were cultured in vitro according to a 
modification of the Mishell-Dutton method (42). Briefly, WS (5-lOxlO^/ml) 
and SRBC's (25A of 1% SRBC) were suspended in roughly 1ml of culture 
media containing RPMI 1640, FCS, antibiotics, a fungicide, and 2- 
mercaptoethanol. Individual cultures included WS plus SRBC, to which 
BMC suspended at a concentration of 30x10^ cells/ral could be added. 
All experimental groups were represented by triplicate culture wells 
in Falcon 3008 culture plates. Primed WS was obtained from mice that 
had been injected with 0.2ml of 1% SRBC, intraperitoneal, 5 days before 
sacrifice. Cells were cultured for 5 days at 37°C in an incubator 
containing a 5% CO^ atmosphere. 
B. Assay: Cultures were assayed via the Cunningham modification 
of the Jerne method (45). Briefly, after removal of cells from culture, 
they were washed and brought up to 1ml in BSS. Of this, 100A was added 
to 25A of 10% SRBC, 50A of BSS, and 25A of GPC (diluted 1:3 in BSS) and 
placed in a Cunningham slide chamber, the sides of which were then 
sealed with wax. After incubation for 1 to 1.5 hours at 37°C, the 
slides were examined for clear plaques, each of which represented an 
IgM anti-SRBC secreting cell. The number of plaques in each chamber 
was multiplied by 40 (to account for cell dilution in the assay) to 
yield the total plaque forming cells/culture (PFC/culture). Each well 
was individually assayed and triplicates were averaged to obtain the 
PFC/culture for each experimental group. Suppression within experi¬ 
ments was determined by comparison to control WS cultures and was 
calculated by the formula: 
% suasion = a - ™ 
- 
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C. Conditioned Culture Media: In one set of experiments, media 
obtained from one to five day old WS + BMC + SRBC cultures was mixed 
with an equal volume of fresh media to make conditioned culture media. 
VI. Colony Forming Units Assay 
The generation and measurement of colony forming units in the 
spleen (CFU-S) was carried out as described by Till and McCulloch (46). 
In brief, mice were exposed to whole-body x-irradiation totaling 900 rads 
or 500 rads and were then injected with 0.2ml of syngeneic donor mouse 
BMC suspension by lateral tail vein between 2 and 5 hours after irradia¬ 
tion. Although 500 rads of whole-body irradiation is not lethal, as 
900 rads is, the fraction of endogenous CFU-S that survive is less than 
1% (47), so that the data from these mice can be reasonably compared to 
the lethally irradiated mice. This is supported by the lack of any 
differences seen in those experiments in which both dosages were used. 
The recipient mice were housed in laminar flow hoods, with tetracycline 
in their water, for 7 to 10 days, at which time they were sacrificed 
and their spleens removed. After fixation in Bouin's solution for 
18-24 hours, the spleens were examined under 1.7 x magnification for 
white nodules, each of which represented a CFU-S arising from one cell 
(48). Control irradiated mice in which no cells were injected never 
yielded more than 1 CFU/spleen and usually were devoid of any CFU-S. 
VII. Statistics 
All statistics were derived from a 2-tailed student's t-test for 





The phenomenon of BM suppression is shown in Table 1. In these 
experiments, the response of WS to SRBC's in in vitro culture conditions 
is modified by the addition of syngeneic BMC to the culture. Table 1 
6 6 
demonstrates how the addition of as few as 1x10 BMC to 5x10 WS fre¬ 
quently suppressed the WS response to less than 50% of control WS values 
for both primary and secondary WS responses. In all cases 3x10^ BMC 
was profoundly suppressive. Figure 1 illustrates the roughly linear 
dose response curve that results as the addition of increasing numbers 
of BMC progressively decreases the PFC response. 
That this phenomenon is not particular to C57BL6 mice is apparent 
from Table 2, which shows that of 14 mouse strains tested, all signifi¬ 
cantly suppressed a syngeneic WS response, 13 to less than 50% of control 
cultures, while one completely abolished the generation of PFC's. 
Phenotype of the BMSC 
Identification of cell-surface markers on the BMSC was carried out 
using both positive and negative selection techniques, as shown in 
Tables 3 through 7. In Table 3, experiments 1-4, utilizing antisera 
directed at several standard T cell markers, were unsuccessful in 
removing BM suppression. Experiment 5 also indicates that cells with 
phenotypes known to characterize natural killer cells (49) do not appear 
to mediate the BM suppression. Experiments 6 and 7 demonstrate, however, 
that the BMSC does carry surface major histocompatibility antigens, since 
anti-H-2 antisera + complement (C) treatment of BM removes its suppressive 
activity. The non-T cell nature of the BMSC is confirmed in Table 4, 
in which it can be seen that mice lacking T cells, namely athymic nude 




Induction of surface Thy-1 antigen was attempted. Table 5, by 
preincubation of BMC in thymopoietin solutions. If the BMSC is a pre¬ 
cursor T cell, this maneuver should either deplete the ranks of BMSC's 
through maturation, or make the BMSC a Thy-1+ cell. It is clear from 
these experiments that neither situation exists, since both control and 
anti-Thy-1.2 + C treated BMC's are profoundly suppressive. 
The possibility of surface Ig (slg) expression by the BMSC is 
addressed by two different methods in Table 6. The first 2 experiments, 
utilizing goat anti-mouse Ig coat petri plates to positively select 
for slg+ cells, demonstrate that following BM fractionation, the sup¬ 
pressive activity migrates with slg fraction. Experiments in which 
the BMC were first preincubated with dibutyryl-CAMP to induce slg prior 
to slg fractionation yielded identical results (data not shown). Mice 
who have had chronic exposure to an anti-ju antiserum from birth have 
been shown to possess little or no slg+ cells (38). It is easily 
appreciated from experiments 3 and 4 that such mice are not depleted 
of their BMSC's. 
Finally, in Table 7, the BMSC was tested for the presence of an 
Fc receptor (FcR), as determined by cell adherence to SRBC's coated 
with goat anti-SRBC antiserum. This experiment shows the adherent frac¬ 
tion (i.e. - the FcR+ cells) possesses very little suppressive activity 
while the non-adherent, FcR , fraction is quite suppressive. 
Mechanism of Action of the BMSC 
+ 
Although the BMSC was not an Ly-2,3 cell, there was the possibility 
+ 
that it was recruiting Ly-2,3 cells in the WS to generate suppression. 
This possibility was ruled out by experiments, depicted in Table 8, in 
which the removal of Ly-2,3+ from the WS did not alter the degree of 
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suppression delivered by BMC's. Experiment 1 extends this result by 
showing that the complete removal of Ly-2,3+ from WS and BMC's was 
also without effect, as indicated by the 98% suppression of the WS 
response seen under these conditions. 
In Table 9, supernatant media from the usual BMC + WS + SRBC 
cultures was obtained from one to five day old cultures and subsequently 
used as conditioned culture media to explore the possibility of a 
soluble factor that would mimic the BM suppression. When such media 
was used on WS + SRBC cultures, absolutely no suppressive effects were 
observed, indicating that the suppression generated by BMC's is not 
mediated by a stable soluble factor. 
Genetic Restriction of BMSC Activity 
Given the ubiquitous presence of the BMSC in the mouse strains 
tested, an analysis of the genetic restrictions of its activity was 
undertaken, with representative results shown in Table 10 and 11. 
Experiments 1 through 3 in Table 10 demonstrate that limited, well- 
defined genetic mismatching between the BMC and WS does not alter the 
BM suppression observed. While these experiments show that Mis, U kappa 
and V mismatches are irrelevant, experiment 4 furthers this observation 
Li 
to include the background genome. Here suppression was seen even when 
the BMC-WS homology was limited to the H-2 and Mis loci. 
In Table 11, it can be seen that genetic mismatching between the 
BMC and WS, to the extent of being essentially random, has no effect 
upon the BM suppressive activity. Experiments 1 through 3 show that 
H-2 mismatching, in the presence of assorted other genetic differences 
(including Mis, U kappa, and V ) still resulted in BM suppression of 
ri 
the WS response. 
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BM Suppression is Less in Neonatal Mice 
BMC of neonatal (less than 14 days old) mice, was cultured in 
vitro with syngeneic WS to examine its suppressive activity. Table 12 
gives representative examples of many such experiments. While experi¬ 
ments 1 and 3 used unprimed WS and experiment 2 used SRBC-primed WS, 
all three showed that neonatal BM much less suppressive than its adult 
counterpart. Even in the least dramatic example, experiment 3, the 
neonatal BM generated only half the suppression expressed by the adult 
BM. In general, the addition of neonatal BMC's to WS + SRBC cultures 
resulted in less than 30% suppression of the WS response (pooled data 
from more than 15 separate experiments). Figure 2 shows two other 
experiments in which the dose-dependent BM suppression of neonatal BM 
is compared to adult controls. At every dose tested, neonatal BMC's 
were clearly less suppressive than its adult control. 
Table 13 shows 3 representative examples of efforts to characterize 
this phenomenon. In these experiments, as in all similar ones performed, 
treatment of the neonatal BMC with anti-Thy-1.2 + C resulted in increased 
suppression. Of note is that the complement controls also reflect a 
moderate increase in suppression. This effect, which will be discussed 
later, was most pronounced with rabbit complement and prevented the use 
of anti-Ly antisera (all of which are compatible only with rabbit comple¬ 
ment) for further phenotyping. The experiments in Table 13 used guinea 
pig complement. 
While these experiments indicate that a Thy-1+ cell was reducing 
neonatal BM suppression, the relevance of this phenomenon to BM suppres¬ 
sion in the adult was not a. priori straight forward. Through simple 
mixing experiments, presented in Table 14, it was possible to determine 
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what effects, if any, the neonatal BMC’s might have upon the adult 
£ 
BMSC. Experiments I and II show that the addition of 1x10 neonatal 
£ 
BMC to 3x10 adult BMC reduces the adult BM suppression by up to 21%. 
Furthermore, as the proportional contribution of neonatal BMC towards 
the total number of BMC used increases, the level of suppression de¬ 
creases. This demonstrates that the neonatal BM contains a contra- 
suppressor activity that reduces the suppressive activity of the adult 
BMSC. 
Increased Contrasuppressor Activity is Seen in Some Adult Mice 
In the process of determining the strain distribution of the BMSC, 
it was discovered that 3 CBA substrains showed reduced levels of BM 
suppression as adults. Table 15 shows representative examples demon¬ 
strating that the CBA/CaJ, CBA/H, and CBA/N mice have markedly less 
suppressive BM than CBA/J mice. From Table 16 it can be further said 
that this low level of BM suppression can be largely, if not entirely, 
ascribed to a Thy-1+ cell that masks BMSC activity. This is in agree¬ 
ment with the results obtained for neonatal BM, making it likely that 
the CBA/CaJ, CBA/H, and CBA/N mice possess a contrasuppressor cell 
similar, if not identical, to the neonatal contrasuppressor. 
The Contrasuppressor is Not Simply a Helper Cell 
To answer the question of whether the contrasuppressor was simply 
a helper cell that did not directly affect the BMSC activity, BMC's 
adherent to the lectin V. Villosa, which does not bind T helper cells 
(see Methods), were used as a source of contrasuppressor cells. Table 17 
shows two experiments which demonstrated that the V. villosa adherent 
cell population was depleted of BM suppression. Experiment 2 also shows 




suppressor population since anti-Thy-1 + C treatment of these cells 
results in profound suppression. Equally clear is that the adherent 
cell population is unable to deliver help to B cells, making it ex¬ 
tremely unlikely that the BM contrasuppressor is simply a helper cell. 
Rabbit Serum Contains an Anti-Mouse BM Contrasuppressor Activity 
It had been noted in many experiments that treatment of BMC with 
rabbit complement (RC) served to increase suppression. Although this 
was most noticeable in those mice with high levels of contrasuppression, 
it was detectable in virtually all mice. Because this severely limited 
the ability to phenotype the contrasuppressor cell, a closer examination 
of this phenomenon was undertaken. 
As shown in Table 18, initial experiments demonstrated that heat- 
inactivated RC possessed decreased anti-contrasuppressor activity than 
untreated RC, as reflected by the greater suppression manifest by Re¬ 
treated BMC than by heat-inactivated RC-treated BMC. While this did 
not identify the anti-contrasuppressor cell activity beyond implicating 
the complement cascade as a necessary component , experiment 2 implied 
that an antigen-specific factor was involved. In this experiment, 
RC absorbed with BMC was relatively ineffective for removing the contra¬ 
suppressor, although it still contained an intact complement pathway 
(see Methods). The specificity of the RC factor can be inferred from 
the negligible effect of absorbing the RC with spleen cells. 
Table 19 shows experiments that further identify the RC antigen- 
specific factor. In Experiments 1 and 2, heat-inactivated RC was used 
as a source of RC factor and guinea pig complement (GPC) - which has 
low anti-contrasuppressor activity - was used as a complement source. 
In both cases, the cytotoxicity of GPC was virtually doubled by the 
' 
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addition of heat-inactivated RC. A more clear-cut example is Experi¬ 
ment 3, in which the ammonium sulfate precipitable fraction of RC - 
a fraction that is at least 70% Ig (see Methods) - is used as an RC 
factor source. This experiment clearly shows that the cytotoxic 
factor in RC is contained in the ammonium sulfate precipitable fraction 
and is likely of immunoglobulin origin. 
Regulation of BMC-Derived CFU-S and Hematopoiesis 
In an attempt to discover the physiologic significance of the 
BM regulatory circuit elucidated from in vitro cultures, the effect of 
perturbating the BMSC-contrasuppressor cell balance upon BMC-derived 
colony forming units in spleens (CFU-S) was investigated. Approaching 
this question through standard techniques, BMC were Thy-1 depleted by 
anti-Thy-1 + GPC treatment, using GPC that was screened for low anti- 
contrasuppressor cell activity. Figure 3 gives the results of 3 experi¬ 
ments in which untreated or Thy-1 depleted BMC were adoptively trans¬ 
ferred to irradiated syngeneic mice. Using CBA/N (Experiment 1) or 
CBA/CaJ (Experiments 2 and 3) mice to maximize the sensitivity of the 
experiments, it was found that Thy-1 depleted BMC expressed fewer 
CFU-S in all experiments. 
Figure 4 presents the results of other pilot experiments, in which 
untreated or RC-treated BMC were adoptively transferred to irradiated 
syngeneic mice. It can be seen that, in every case, RC treatment of 
BMC reduces CFU-S expression. The possibility of a RC-sensitive CFU-S 
"helper" cell is addressed in Table 20, in which untreated and RC- 
treated BMC are given alone or in combination to irradiated mice. In 
both experiments the RC-treated BMC not only express fewer CFU-S than 
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untreated BMC but, when the former is added to the latter suppression 
of untreated BMC CFU-S expression is apparent. This implies that a 
suppressor cell for CFU-S expression is being unmasked by RC-treatment 
of BMC. 
In apparent conflict with these results were the experiments 
in Table 21, in which adult and neonate BMC CFU-S generation are 
compared. These two experiments clearly show that the adoptive 
transfer of neonatal BMC resulted in significantly fewer CFU-S than 
similar numbers of adult BMC. This is the opposite of what would be 
expected if CFU-S expression was primarily determined by the level of 
contrasuppression. 
Addressing the question of the physiological role of BM contra¬ 
suppression from another direction, mice were made anemic through 
periodic phlebotomy and their BMC was tested for in vitro suppression. 
Figure 5, which shows the results of two such experiments, demonstrates 
that anemic BMC produced only half the level of suppression manifested 
by the control BMC. Furthermore, after treatment of the anemic BMC 
by anti-Thy-1 + GPC, the BMC suppression increased from 18% to 31% in 
Experiment 1 and from 21% to 47% in Experiment 2. Regardless of 
whether the anti-contrasuppressor agent is the antisera or the GPC, 
it is clear that increased contrasuppression is contributing to the 
lower BM suppression seen in anemic mice. In addition, simple dilution 
of the BMSC secondary to active hemoproliferation is an unlikely ex¬ 
planation for the reduced BM suppression as the anemic BM was not 
any more cellular than the control BM. 
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The Effect of Parathyroid Hormone on BM Suppression 
In further explorations of BM physiology, the effect of para¬ 
thyroid hormone (PTH), which increases osteoclast activity in bone, 
upon in vitro BMC cultures was examined. Figure 6 shows the results 
of 3 such experiments in which the pretreatment of BMC with PTH - note 
that the PTH is not present during in vitro culture - significantly 
(P .05) decreases the BM suppression generated by those BMC. A dose- 
response curve of BM suppression delivered by PTH-treated BMC, Figure 7, 
indicates that the PTH treatment alters the kinetics of BM suppression, 
as reflected by the different slopes seen for control and PTH-treated BMC. 
In summary, the data presented depicts the interactions ot two cells 
found in murine bone marrow. The first, partially described by others 
(19,20,21,22,24,25), is the BMSC, which can be seen to be a cell lacking 
in all standard lymphocyte markers (Tables 3,4 and 6). This cell is 
further differentiated from the classical T suppressor cell by the former's 
ability to suppress allogeneic lymphocyte responses (Table 10 and 11). 
The second, a newly described cell called a BM contrasuppressor, 
acts to reduce the suppression generated by the BMSC (Table 14). This 
cell is Thy-1+ (Table 13) and is found in certain adult CBA mice 
(Table 16), but is definitely not a T helper cell as it does not aid B 
cells in the production of antibodies (Table 17). Furthermore, the 
presence of BM contrasuppression correlates with increased hematopoietic 
activity, either as measured in the CFU-S assay (Figures 3 and 4, Table 20) 
or as seen as an accompaniment to in vivo anemia (Figure 5). Finally, 
PTH treatment of BM results in reduced jin vitro BM suppression (Figures 6 
and 7), implying that the balance between BM suppression and contra¬ 
suppression may be altered by activation of a PTH receptor. 

TABLE 1 
BMC SUPPRESS BOTH PRIMARY AND SECONDARY IN VITRO SPLENIC 






BMC Added Primary Secondary Suppression 
None , 2387 — 
1 x 106 
893 63 
3 x 106 13 100 
None , 4427 — 
1 X 106 
2560 42 
3 x 106 80 98 
: 106 BMC cult. 
alone 
13 —- 
None , 1520 — 
2 x 106 
1093 28 
3 x 106 200 81- 
None , 8000 — 
2 x 10* 427 95 
3 x 106 293 96 
1. BMC mixed with 5 x 10 WS for rn vitro culture (see Methods). Spleen 
cells were from naive mice ("primary") or from mice innoculated at 
least 4 days before sacrifice with 0.2 ml of 1% SRBC i.p.("secondary"). 












BMC SUPPRESSOR ACTIVITY IS 
DOSE DEPENDENT 
B MC ADDED ( X io"6) 
1 
E X P I EXP 2 
£ 
1. C57B16 BMC added to 5 x 10 primed syngeneic WS for ini vitro 
culture as detailed in Methods. WS controls were 19,440 and 
4400 PFC/culture in experiments 1 and 2, respectively. 

TABLE 2 
BMSC ACTIVITY IN COMMON STRAINS OF INBRED MICE 
Strain_Haplotype BMC Added_PFC/Culture %Suppression 
C57B16 H-2b _ 1520 — 
+ 200 87 
Balb/cJ H-2d - 2120 — 
+ 613 71 
DBA/2 H-2d - 907 — 
b. + 253 72 










+ 573 76 
BIO. S H-2S - 3133 — 
H-2s/d 
+ 1760 44 
A.TH - 533 — 
+ 253 53 
CBA/J H-2k - 3693 — 






+ 467 68 
(B6 X A)Fl - 2533 — 




+ 547 86 
1. 5 x 106 WS cultured alone (-) or with 3 x 10b syngeneic BMC (+) as 
















































<r co O O 




























cr a) 0J s 
c c co -h 
CJ CO 
C JC 4J 
O CQ CU 
o 
(33 
C 0) u 
B o 








co 03 -u 
4=4 
r-H 5-4 T3 
3 CU 0) CO 4J T3 0} 4-5 T3 05 <C fl3 

TABLE 4 
BONE MARROW SUPPRESSION IS PRESENT 
IN MICE LACKING T-CELLS 
Experiment_BMC Added^_PFC/Culture_%Suppression 
none 400 
I Balb/ByJ 53 87 
Balb/ByJ nude 13 97 
none 2533 
II B6AF1 0 100 
B6AFX "B"1 2 0 100 
1. 3 x 10^ BMC added to 5 x 10^ WS. Spleen cells from Balb/ByJ and 
B6AF^ mice in experiments I and II, respectively. See Methods. 
2. B6AF. "B" mice depleted of T-cells by thymectomy followed by lethal 
irradiation and reconstitution with anti-theta + RC treated 




THYMOPOIETIN DOES NOT INDUCE THY 1.2 SURFACE 





BMC Added ws —- 











1.0 2240 13 13 
0.1 293 13 
0.01 27 13 
0.001 40 0 
1. Thymopoietin (TP) was diluted in RPMI 1% FCS to the concentrations indicated 
BMC were then incubated in one of the solutions for 2 hrs. at 37 C, thoroughly 
washed, counted, and subsequently treated with either complement alone (C) or 
a -Thy 1.2 + C before being added to WS for in vitro culture (see Methods). 
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TABLE 7 









- - — + 2907 
+ - - + 480 
- + - + 2120 
_ _ + + 667 
£ 
1. C57B16 BMC added to 5 x 10 syngeneic WS fgr in vitro culture as 
detailed in Methods. BMC added was 3 x 10 (unseparated BMC) or 
its equivalent (F adherent or F non-adherent BMC) as explained 
in Methods. 
2. Cells harvested from petri dishes covered with anti-SRBC Ig coated 
SRBC's. Adherent cells are F receptor positive while non-adherent 
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BMSC ACTIVITY IS NOT RESTRICTED BY Mis, V KAPPA, V„, OR 
—--—- ————, ■ -—  —■ ■ — _ n — 
BACKGROUND GENETIC DIFFERENCES 
Experiment BMC Added1 WS Added PFC/Culture % Suppression 
1) None CBA/CaJ 6360 
CBA/CaJ (Mlsb) It 1360 79 
CBA/J (Mlsd) 
If 800 87 
2) None C57B16 8747 
C57B16 
(Lyl.2,2.2,3.2) 
II 307 96 
M 16 
(Ly1.2,2.1,3.1) 
» 120 99 
None M 16 7067 
M 16 It 133 98 
C57B16 If 173 98 
3) None Balb/c 1867 
Balb/c 
(Igl3) 
It 493 74 
CB .20 
(Iglb) 
If 147 92 
None CB .20 1000 92 
Balb/c If 80 96 
CB .20 
It 40 
4) None DBA/2 3840 




1. In vitro cultures using 3 x 10 6 BMC and 5 x 10b WS were prepared and assayed 
noted in Methods. The mouse strains in experiments 1-3 are known to possess genetic 
differences at the loci indicated in parentheses, while the mice in experiment 4 
have dissimilar background genomes and identical H-2 and Mis loci. 
* 
TABLE 11 





(haplotype) PFC/Culture (% Suppression) 
1) None C57B16 (H-2b) 1347 
Balb/c (H-2d) 
If 387 (72) 
CB.20 (H-2d) 
If 253 (81) 
2) None C57B16 (H-2b) 4400 
DBA/2 (H-2d) 
It 1240 (72) 
3) None CBA/CaJ (H-2k) 4120 
C57B16 (H-2b) II 240 (94) 
1. In vitro cultures using 3 x 10 BMC and 5 x 10 WS were prepared and assayed 
as detailed in Methods. BMC and WS were obtained from mice mismatched at 
H-2, with the relevent alleles indicated in parentheses. 

TABLE 12 
NEONATAL BM IS LESS SUPPRESSIVE THAN ADULT BM 
Experiment BMC Added1//BMC/Neonate2 PFC/Culture%Suppression 
1) None 1520 
Adult 200 87 
Neonate (7-9 d) 9.7 x 106 1720 0 
2) None 1800 
Adult 0 100 
Neonate (10 d) 12.5 x 106 2820 0 
3) None 2413 
Adult 573 76 
Neonate (11-13 d) 19.2 x 106 1453 40 
1. BMC obtained from tibias and femurs of all adult and neonatal mice. All adult 
mice were at least 8 weeks old^while neonates were of the ages indicated in 
parentheses (in days). 3 x 10 BMC were cultured in vitro with 5 x 10 syngeneic 
WS as detailed in Methods. Mice used were C57B16, C57B16, and B10.4R in 
experiments 1, 2, and 3, respectively. 
2. The pooled mean //BMC/mouse efter flushing BM from femurs and tibias. Numbers 




















DOSE RESPONSE OF NEONATAL BMC 
1 00 
Ex p 1 E x p 2 
BMC ADDED (X 10*6) 
1 
6 
1. C57B16 BMC added to 5 x 10 syngeneic WS for in vitro culture as 
detailed in Methods. WS controls were 19,440 and 3120 PFC/culture 
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TABLE 14 
NEONATAL BM CAN REDUCE ADULT BM SUPPRESSION 
Experiment 
Total 
BMC Added1 %Neonatal BMC2 % Suppression 
None WS control-1814 
3 x 106 0 56% 
I 
4 x 106 25 43% 
3 x 106 100 24% 
None — WS control-2413 
3 x 106 0 76% 
II 
4 x 106 25 55% 
3 x 106 30 51% 
4 x 106 50 59% 
3 x 106 100 40% 
1. BMC added to 5 x 10 syngeneic WS for in vitro culture (see Methods). Mouse 
strains used were B10.3R and B10.4R in experiments I and II, respectively. 
2. The fraction of total BMC added that came from neonatal mice. 

TABLE 15 
CERTAIN CBA SUB-STRAINS HAVE LOW LEVELS OF 
BM SUPPRESSION AS ADULTS 
Experiment BMC Added PFC/Culture %Suppres; 
1) None 1206 
CBA/ J 320 73 
CBA/CaJ 960 20 
2) None 7380 
CBA/ J 1280 83 
CBA/H 7200 2 
3) None 2067 
CBA/ J 453 78 
2 
CBA/N (homozygous) 1907 8 
CBA/N (defective F^) 2013 3 
CBA/N (nondefective F^) 2093 0 
A 
1. 3 x 10 BMC added to 5 x 10 WS for in vitro culture (see Methods). WS 
used was CBA/CaJ, CBA/CaJ, and CBA/N (nondefective Fp in experiments 
1, 2, and 3, respectively. 
2. Homozygous CBA/N females mated with C57B16 males to produce defective (male) 
and nondefective (female) F^ heterozygotes. 

TABLE 16 
ADULT BM WITH LOW SUPPRESSION HAS A Thy 1+ BM CELL 
THAT REDUCES BM SUPPRESSION 
1 2 
Experiment_BMC Added _BMC Treatment _PFC/Culture (%Suppression) 
1) None - 680 
CBA/CaJ None 1080 (0) 
If Complement (C) 707 (4) 
II a-Thyl.2 + C 307 (55) 
2) None — 7380 
CBA/H None 7200 (2) 
II C 2160 (71) 
II a-Thyl.2 4- C 649 (91) 
3) None — 2067 
CBA/N 
(nondefective F^) 
None 2013 (3) 
11 C 2267 (0) 
If a-Thy1.2 + C 1307 (37) 
f) £ 
1. 3 x 10 BMC added to 5 x 10 WS for in vitro culture (see Methods). WS used 
in experiments 1, 2, and 3 were CBA/J, CBA/CaJ, and CBA/N (nondefective F^), 
respectively. 
2. Complement used in antisera treatments was "low tox" (see Methods) in experiments 
1 and 3, while guinea pig complement was used in experiment 2. 

TABLE 17 
THE BMC FRACTION ADHERENT TO PLATES COATED WITH 
THE LECTIN V. VILLOSA IS ENRICHED FOR 
CONTRASUPPRESSOR ACTIVITY 
. Spleeij Cells 
Experiment_BMC Added_Added_PFC/Culture 
None WS 1720 
Unseparated WS 1280 
Non-adherent WS 680 
Adherent WS 2200 
None WS 4120 
Unseparated WS 1080 
Non-adherent WS 1240 
Adherent WS 4600 
Adherent, treated 
(a-Thy1.2 + C) 
WS 1600 
None B Cells 0 
Non-adherent B Cells 0 
Adherent B Cells 0 




1. 3 x 10 BMC (or its equivalent) were added to 5 x 10 syngeneic WS or 
B cells as detailed in Methods. BMC were fractionated according to their 
adherence or non-adherence to plates coated with the lectin V. Villosa 
(see Methods). Mice used were neonatal C57B16 and adult CBA/CaJ, in 
experiments I and II, respectively. 
2. B cells and T cells were fractionated from WS by their adherence (B cells) 
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THE RABBIT SERUM ANTI-MOUSE BM ACTIVITY RESIDES 
IN THE Ig ENRICHED FRACTION 
heat RC Preparation 
Experiment BMC Used1 
2 
GPC 
inactivated Rig , 
RC1 3 4 5 (dilution) 
+ 5 
GPC 
1) CBA/N,F1 36 %6 31% 65% 
2) Neonate 34% 66% 
Adult 34% 52% 
3) CBA/CaJ 11% 17% 50% 
(1:10) 
CBA/CaJ 11% 9% 48% 
(1:20) 
1. Mice used in experiment 2 were Balb/cByJ. BMC were exposed to the preparations 
indicated in cytotoxicity assay (see Methods). 
2. Guinea pig complement (GPC) used at 37°C for 30 minutes. 
3. RC first inactivated by heating to 56°C for 30 minutes,then used as for GPC. 
4. The NH^SO^ precipitate of rabbit serum resuspended in a minimum volume of PBS 
then diluted and used as for GPC (see Methods). 
5. The rabbit serum (RC) preparation used in each particular experiment was used 
to resuspend the BMC for 30 minutes at 4 C. The BMC were then washed and 
exposed to GPC for 30 minutes at 37°C. 
6. Results expressed as %cytotoxicity from the treatments indicated. 
. 
FIGURE 3 
CFU-S EXPRESSION BY BMC IS 
PARTIALLY THY1 DEPENDENT 
BMC 
1. 10^ BMC injected into irradiated syngeneic hosts (see Methods). 
Mice used in experiments 1,2, and 3 were CBA/N (4/group), CBA/CaJ 
(4/group), and CBA/CaJ (3/group), respectively. 
2. BMC treated with anti Thyl.2 antisera + GPC. The GPC control 
was 11.0 CFU-S/10"* BMC in exp. 2. 

FIGURE 4 
RABBIT COMPLEMENT TREATMENT 
REDUCES BMC - DER I VED CFU-S 
1. BMC injected into irradiated syngeneic hosts (see Methods).^ 
Mice used in experiments 1,2 and 3 were C^D^F. (2/group, 10 
BMC injected), BDF. (2/group, 10 BMC injected), and CBA/CaJ 
(2/group, 5 x 10 BMC injected), respectively. 
2. BMC exposed to RC for 30 minutes at 37°C before injection. 

TABLE 20 
RABBIT SERUM TREATED MURINE BM SUPPRESSES CFU-S 




Untreated BM RC-treated BM CFU-S/10 BMC' 
10° - 5.2(4- 0.2) 
I - 106 2.8(4 1.5) 
106 io5 2.8(4 0.4) 
10 - 5.5(4 0.2) 
II - io5 4.0(4 1.5) 
io5 io4 1.0(4 0.1) 
1. Lethally irradiated mice reconstituted with syngeneic BMC 
Experiment I used C-2^3^1 mice and experiment II used BDF^ 
mice in each group. 
(see Methods). 
mice, with two 
2. (+ S.E.) . 

TABLE 21 





Adult BMC Neonate BMC CFU/spleen 
I 
4 
3 x 10 
4 






3 x 10 
1 x 105 
4 
3 x 10 







1. Lethally irradiated C57B16 mice reconstituted with syngeneic BMC (see 
Methods). Each group in experiment I utilized 5 mice, while those in 
experiment II used 3 mice. 
* 
P< 0.02 when compared to similar mice injected with adult BMC. 
# 






















BMC OF ANEMIC MICE ARE LESS 
SUPPRESSIVE THAN NORMAL BMC 
i oo 
1. 3 x 10 CBA/J BMC added to 5 x 10 (exp. 1) or 10 x 10 (exp. 2) 
syngeneic WS for in vitro culture as detailed in Methods. WS 
controls were 800 andr;2693 PFC/culture in experiments 1 and 2, 
respectively. 
2. Mice made anemic by alternate-day bleeds averaging 0.3 ml. 















PARATHYROID HORMONE MAY 
ACTIVATE THE CS 
6 6 
1. 3 x 10 BMC added to 5 x 10 WS for _in vitro culture (see Methods). 
Experiments 1,2, and 3 involved CBA/J BMC added to CBA/J WS, C57B16 
BMC added to C57B16 WS and C57B16 BMC added to CBA/CaJ WS, 
respectively. C57B16 mice obtained from Charles River Labs (exp. 2 
and 2 matched*; groups in exp. 3) or Jackson Labs (2 matched groups 
in exp. 3 ) . 
2. BMC exposed to PTH before in vitro culture (see Methods). 
3. P< .05 for paired t-test involving exp. 1 only, exp. 2 and 3 only, 















DOSE RESPONSE OF 8M SUPPRESSION 
AFTER PTH TREATMENT 
-6 1 
BMC ADDED (X 10 ) 
£ 
1. C57B16 BMC added to 5 x 10 syngeneic WS for ini vitro culture 
as detailed in Methods. WS control was 1800 PFC/culture. 
2. BMC exposed to PTH before in vitro culture (see Methods). 

DISCUSSION 
I. Characterization of the BMSC 
It has been appreciated for some time that the bone marrow contains 
a population of cells that are capable of suppressing an in vitro 
antibody response by lymph node (19) or spleen (18,20,22,23,25,50,51) 
cells. A definitive characterization of this population has, as yet, 
eluded investigators, however. 
It seems probable that the bone marrow suppressor cell is not a 
macrophage or other phagocytic cell, as identified by the presence of 
an Fc receptor (52) or glass adherence (53). All attempts to demon¬ 
strate a glass adherent or indomethacin sensitive suppressive activity 
(data not shown) or to detect an Fc receptor positive BMSC (Table 7) 
met with failure. With the exception of one report (20), others have 
also been unable to characterize the BMSC as a glass/plastic adherent 
(19,25) or carbonyl-ingesting (18,50) cell. Data concerning a BMSC Fc 
receptor is less compelling, with one report of a Fc receptor positive 
suppressor cell (18), while another suggested that a subpopulation of 
BMSC's may be Fc receptor positive although enrichment for suppression 
was not observed in the Fc receptor positive fraction of BMC (20). 
Some have inferred from radiosensitivity data, which showed BM suppres¬ 
sion to be abrogated by 800-1000 rads of x-irradiation (20,51), that the 
BMSC was not a macrophage, although one group (22) identified a BM 
suppressor that was sensitive to as little as 50 rads. Despite a certain 
amount of conflicting data, the evidence predominately favors the con¬ 
clusion that the BMSC is not a macrophage. 
The possibility of B cell mediated BM suppression was examined by 
two different techniques. The use of positive selection via Ig plates 





pool of BMC simultaneously. The data unequivocally show that the 
BMSC is slg and, furthermore, that no suppressive activity can be de¬ 
tected in the slg+ fraction. Complementary experiments using BMC from 
u-suppressed mice lacking mature B cells (38) demonstrated that these 
mice did not have decreased levels of BM suppression. These data, then, 
do not provide any evidence to support the notion that the BMSC is an 
slg+ B cell. Past efforts to detect slg on the BMSC have had mixed 
results, with some unable to demonstrate slg using anti-Ig columns (18) 
or anti-Ig antisera + complement treatments (20), while others (19,21) 
were more successful. The data of Fuch, j2t al (21) in particular, 
strongly implies an slg+ BMSC and it is difficult to explain the marked 
discrepancy between their data and that presented here. 
The first immunosuppressive cell described (10) was a T cell, as 
defined by its cell surface antigens (54). That the BMSC might also be 
a T cell is a natural extension of the suppressor cell concept that was 
explored. The use of antisera directed at Thy-1 (5), Ly (54), I-J (55), 
and Qa (56) cell surface antigens to subdivide T lymphocyte populations 
is a well-established technique that was employed in these investigations. 
It was abundantly clear (Table 3) that BM suppression was not sensitive 
to any of these agents. Of some interest was that anti-brain associated 
theta (BAT) antisera, which has been reported to have specificities for 
stem cells (57,58), non-T cells (59), pre-T cells (60,61), and some B 
cells (60,62) in the spleen and BM, was equally ineffective in removing 
the BMSC. This data is consistent with the observations that fully 
potent BMC suppression is found in both congenitally athymic nude mice 
and experimentally produced T depleted athymic "B" mice (Table 4). 
Attempts to induce Thy-1 on the BMSC by exposing the BMC to thymopoietin, 
a potent inducer of Thy-1 for precursor T cells (43,44), were also un- 
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successful (Table 5). Although there is some evidence that differentia¬ 
tion may occur in vitro without stimulation (63,64), preculture of 
BMC for 24 hours neither induced a Thy-1 BMSC nor reduced overall BM 
suppression (data not shown). The compelling conclusion is that the 
BMSC is certainly not a mature T cell and is very unlikely to be a 
precursor T cell. Other investigators (19,20,22,24), notably Singhal 
(18,25,50,65), generally using heterologous anti-0 antisera, have simi¬ 
larly concluded that the BMSC was not a T cell, although the possibility 
of a weakly 9+ cell possessing other T cell markers was not examined. 
There has been some uncertainty over whether the BMSC is a precursor T 
cell, with Dauphinee and Talal reporting a BMSC with inducible 9 (22) 
while Corvese, et^ al (20) were unable to find such a cell. The source 
of discrepancy appears to be the method used for fractionation of BMC. 
Dauphinee and Talal studied a density gradient fraction that was en¬ 
riched for lymphocytes while Corvese, e_t al used BMC that were either 
unfractionated or lymphocyte depleted. In as much as Gorcznski and 
MacRae (24) showed that the BMSC comigrated with large polymorphonuclear 
cells during velocity sedimentation and Corvese, et al (20) found that 
suppressive activity was inversely related to the percentage of lympho¬ 
cytes found in each fraction after free-flow high voltage electro¬ 
phoresis of BMC. It is likely that the suppressor cell of Daupinee and 
Talal is a low-9 classical suppressor cell that migrated to the BM. 
That such peripheral blood lymphocytes can reside in the BM is well 
known (66). 
It was also found that the BMSC did not bear surface markers 
that are associated with natural killer cells found in the BM (49). 
This was the first demonstration that the BMSC is Ly-5 and N.K. 
(Table 3), although some hint of this is contained in earlier work. 
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Natural killers require the presence of a viable BM (49) and they can 
89 
be shown to decrease in activity after Sr treatment to obliterate 
the BM (49,67). Of note is the observation (49,67) that under these 
conditions, a non-T, slg , BAT splenic suppressor cell emerges in 
inverse proportion to the decrease in natural killer cell activity. 
This suggests that not only is the BMSC not a natural killer cell, but 
it also appears capable of migrating out of the BM cavity when stressed. 
Although the BMSC at present travels somewhat incognito, experimen¬ 
tal evidence presented here defines the effector arm of BM suppression. 
It is clear from Table 8 that BM suppression does not require the 
presence of a classical suppressor cell, as the complete elimination of 
Ly-2,3+ cells from the in vitro culture system does not abrogate suppres¬ 
sion. This implies that the BMSC acts on either the T helper cell or 
B cell directly. That the BMSC effectively suppresses a secondary WS 
response indicates that the BMSC acts to suppress immunocompetent cells 
rather than to prevent the development of an antibody response. This 
is in full agreement with Duwe and Singhal (23,65), who demonstrated 
BM suppression of B cell cultures supplemented with T cell factors, and 
Corvese, et aT (20), who showed that BM was equally suppressive for 
responses to T-dependent of T-independent stimuli. Thus it would seem 
that the BMSC suppresses B cells directly. 
It is likely that the suppressive activity of BMC requires cell-to- 
cell contact. This conclusion stems from Table 9, which demonstrates 
that the BMSC does not secrete a stable soluble suppressor factor. 
Although no clear contradiction to this result has been reported (19,51) 
there is some controversy over experiments involving double-chamber 
diffusion cultures in which the BMC are separated from the responding 
. 
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lymphocytes by a membrane. Using a membrane of 0.2u pore size, Duwe 
and Singhal (65) were able to generate dose-dependent BMC suppression. 
In contrast, Petrov, et al (68) were unable to demonstrate a soluble 
suppressor factor using a partitioning membrane of 25mm pore size even 
though the membrane was detectably permeable to other secreted BMC 
factors. This lack of a stable soluble suppressor factor is also 
another feature that distinguishes the BMSC from the classical T 
suppressor cell (69). 
If the BMC suppression were passive, in the sense that no cellu¬ 
lar metabolism was required, it might be expected that heat-killed or 
mitomycin-C treated BMC would retain their suppressive activity. 
Although past studies are inconclusive with respect to the suppressive 
capacity of heat-killed BMC (18,19), Singhal (23,50) maintains that BM 
suppression is not abrogated by nitomycin-C treatment, a result that is 
at variance with more recent observations (M. Horowitz, personal 
communication). It is certainly true, though, that intact BMC are re¬ 
quired for suppression to be expressed (25,50). 
The failure of the BMSC to conform to the standard T suppressor 
cell characterizations is perhaps made more understandable by its extra¬ 
ordinary domain of activity. While the induction and action of the 
classical suppressor cell is V and H-2 restricted, respectively 
(69,70,71), the BMSC is effective regardless of the genetic corres¬ 
pondence of the responding spleen cells. Not only does its activity 
breach minor histocompatibility barriers, but major histocompatibility 
(Table 11) and xenogeneic (unpublished observations) differences are 
also irrelevant. A heretofore unappreciated property of the BMSC, 
this probably reflects the unique position that BMC occupy within the 
*# 
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hematopoietic system. Although its ontological development is not 
known, it can be reasonably surmised that, under most circumstances, 
the BMSC is detectable only in the BM and it probably seeks out the BM 
cavity preferentially. Under other circumstances, such selective 
migration of various immunologically active cell populations can be 
demonstrated (66,67,73,74,75,76), indicating that this can serve as a 
generalized response to specific stimuli or homeostatic requirements. 
What is the function of the BMSC that it finds itself largely 
limited to the BM cavity? The extensive hematopoietic role of the BM 
is well known, in general terms at least, but somewhat less appreciated 
is the degree to which the BM participates in antibody production. It 
has been demonstrated by Benner (73,74,77,78,79,80), Cudkowicz (81,82,83), 
and others (72,84,85,86,87), that the BM can serve as a potent source 
of Ab production. In general, this involves formation and migration of 
memory B cells, and probably memory T cells, from the spleen to the BM, 
although at higher antigen doses peripheral lymphoid organs such as 
lymph nodes and Payer's patches can replace the staging function of 
the spleen. The BM contribution to Ab production is minimal during the 
initial response to antigen, but in succeeding Ag challenges, the BM 
becomes the predominant source of Ag-specific IgM and IgG (77,79). It 
should be emphasized that this is a result of lymphocyte migration to 
the BM, since BM probably contains immature or newly mature B cells in 
situ (87) and appears to require T cells for full expression of Ab 
expression (80,87). 
The role of a BMSC in regulating BM Ab production might, therefore, 
seem to be an obvious one. Such a potent suppressor cell in an impor¬ 
tant Ab producing organ has an inherent logic about it that is attrac- 
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tive. Certain inconsistencies must be addressed before this hypothesis 
is accepted, however. Although the BMSC depresses IgM PFC’s more than 
IgG PFC's (23), the data from those groups studying BM Ab production 
indicates that not only is IgM and IgG generated in the BM, but the 
former is usually made in greater quantity (78,83). Duwe and Singhal 
(18) suggest that the BMSC is responsible for the non-Poisson distri¬ 
bution seen in limiting dilution analysis of BMC PFC’s, but this does 
not explain the Poisson distribution obtained in similar experiments 
performed by Cudkowicz, e_t al^ (81), using BDF^ mice, which we have shown 
to possess the BMSC (Table 2). Nor is the question of why IgM PFC's 
are preferentially suppressed fully considered. It has been speculated 
(23) that the BMSC could be the effector cell for clonal deletion of 
autoreactive BM B cells. Although quite alluring, this is incompatible 
with the results of experiments using neonatal BM (Table 12). It is 
well known that exposure to Ag in the neonatal period can render the 
host tolerant to that Ag (88). Consequently, one would expect BM 
suppression to be, if anything, increased during this period of 
"immunological inventory-taking". Experiments show, however, that the 
exact reverse situation was found (Table 12). 
II. The phenomenon of BM contrasuppression 
The finding of decreased BM suppression in neonatal mice contrasts 
with the results of Corvese, e_t al (20) , who found BM of 14 day old mice 
to have adult levels of suppressive activity. This discrepancy is 
almost certainly due to the relatively advanced age of the mice used 
by Corvese, e_t a_l as a sharp increase in BM suppression at about day 12 
of life can be appreciated in Table 12. Furthermore, the reduced BM 
suppression can be attributed to the presence of a Thy-1+ cell that 
interferes with the expression of suppression by the BMSC. 
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Not only does the removal of this cell, the BM contrasuppressor 
cell, increase neonatal BM suppression (Table 13), but also the addition 
of neonatal BMC to highly suppressed adult BMC serves to reduce the 
suppression manifested by the adult BMC. The latter phenomenon also 
partially answers yet another question, that of the ontogeny of BM 
suppression. Theoretically, the development of BM suppression can be 
viewed as the outcome of one of three possible processes: a) a decline 
in the activity of the contrasuppressor, b) a shift in the balance of 
numbers between the BMSC and the contrasuppressor, or c) a developed 
resistance of the BMSC to the contrasuppressor effect. That neonatal 
BMC can act as a source of contrasuppression to reduce adult BM sup¬ 
pression implies that adult BM suppression cannot be completely ascribed 
to BMSC insensitivity to the effector arm of contrasuppression. 
To be sure, this does not identify the effector arm of contra¬ 
suppression on a cellular level. A recently identified cell with 
similar actions (15,16) has been elegantly shown to make T helper 
cells resistant to suppression. Although this demonstration involved 
quite different cell populations of unexplored homology to the BM 
populations, this other contrasuppressor was a T cell that was selec¬ 
tively adherent to the lectin Vicia Villosa (41), making it similar to 
the BM contrasuppressor (Table 17). Thus it is quite possible, if not 
likely, that similar cells and cellular mechanisms are operating in both 
experimental situations. 
The discovery of decreased suppression among certain CBA substrains 
was unexpected. Given the phenotypic identity between the neonatal and 
+ 
CBA contrasuppressors (e.g. both are Thy-1 and selectively adherent to 
Vicia Villosa), it is reasonable to consider them to be identical cells. 
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The only difference between them is that the CBA contrasuppressor is 
present in adult mice, presumably a result of a particular genetic 
endowment (see Appendix II). It has been previously appreciated that 
there are subtle immunogenetic differences between CBA/J and CBA/H 
mice, some of which relate to T-independent antigen responsiveness 
(M. Iverson, personal communication). While this by no means constitutes 
proof, it does suggest that inquiry based upon suitable recombinant mice 
might provide a genetic locus for BM suppression. 
In the course of experiments, it was found that exposure of BMC 
to rabbit complement resulted in greater suppression. Although it was 
usually of little importance in experiments concerned with the BMSC, 
it became a major obstacle in the phenotyping of the contrasuppressor. 
The data in Table 18 give representative examples of the loss of contra- 
suppression caused by rabbit complement. This was seen with all rabbit 
complements used, including commercially available rabbit complement 
screened for extremely low background lymphocyte cytotoxicity, but was 
less evident for guinea pig complement. Interestingly, similar data 
has been published by others without comment (20). This precluded 
further phenotyping of the contrasuppressor, since all available antisera 
directed against Ly, I-J, and Qa cell-surface antigens were only com¬ 
patible with rabbit complement. 
Table 18 also demonstrates that while the anti-contrasuppressor 
activity in RC is somewhat relieved by heating inactivating the RC, 
it was also removed by absorption of the RC with BMC and, to a lesser 
extent, WS syngeneic to the mouse strain used. This suggestion of 
antigen specificity is further explored in Table 19, which shows that 
RC possesses an antibody-like molecule that is directed against BMC. 
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It is likely that this represents heterogeneous immunoglobulin, similar 
in nature to well-described heterophile antibodies seen elsewhere (89), 
with specificities that include the BM contrasuppressor. 
III. The regulation of hematopoiesis 
Another possibility for the role of the BM regulatory circuit is 
in the control of hematopoiesis. In this regard are intriguing reports 
89 
that the spleens of mice treated with Sr, which selectively obliter¬ 
ates the BM compartment, possess a splenic suppressor cell that is 
Thy-1 , BAT , slg , and sensitive to 1000 rads of irradiation (64,67). 
Such mice develop extramedullary hematopoiesis and appear to be similar 
to osteopetrotic mice, whose BM cavity is obliterated by a genetically 
transmitted myelofibrosis and who also express splenic extramedullary 
hematopoiesis in association with a Thy-1 splenic suppressor cell 
(H. Cantor, personal communication). 
In such a role, a decrease in BM suppression would be expected 
under conditions of hematologic stress requiring increased BM production 
of blood constituents. The neonatal mouse is in just such a situation, 
as its rapid growth necessitates a concomitant surge in hematopoiesis. 
Data presented here shows that under these conditions BM suppression is 
drastically reduced (Table 12). Closer examination reveals that once 
the neonate generates more BMC by days 11 to 13, BM suppression increases, 
as would be expected in a regulatory response to prevent uncontrolled 
proliferation. Experiments addressing the question of hematpoiesis in 
CBA mice with high adult levels of contrasuppression have been under¬ 
taken but time constraints have limited the amount of data obtained. 
A series of experiments utilizing the splenic colony forming 
units (CFU-S) assay as a model of hematopoiesis was undertaken to 
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elucidate the regulatory role of BM contrasuppression. Before dis¬ 
cussing the results, a brief description of the CFU-S assay, its 
physiology, and its limitations are warranted. 
The CFU-S assay is quite simple (45). Syngeneic BMC are injected 
intravenously into lethally irradiated mice, who are subsequently 
sacrificed 10 days later and their spleens examined for macroscopic 
nodules, each of which represents a hematopoietic CFU arising from a 
single pluripotent stem cell (90,91). These stem cells, which are 
not morphologically distinctive (46,92) have the capacity to generate 
either myeloid or erythroid CFU's. Although control of differentiation 
can be theoretically attributed to random events, long range factors 
(i.e. hormones), and/or local microenvironmental factors (91,93), the 
last possibility has been clearly shown to be influential (46,94,95, 
96,97). In general, CFU-S tend to be predominantly erythroid (96,97). 
It would be predicted that if the contrasuppressor participated 
in hematopoietic regulation, then removal of the contrasuppressor might 
result in fewer BMC-derived CFU-S. Figure 3 shows that in 3 experiments 
using CBA/N or CBA/CaJ mice, reduction of contrasuppression by treatment 
of the BMC to remove Thy-1+ cells resulted in up to a 50% decrease in 
CFU-S production. Work by others has generally demonstrated reduced 
CFU-S recoverable from BM of neonatally thymectomized mice (28,98,99). 
This condition could be corrected by the implantation of either a 
thymus graft (28) or diffusion chamber containing thymic tissue (27), 
although infusion of thymocytes was without effect (28) and congenitally 
athymic mice have been reported to possess a normal number of CFU-S/10"* 
BMC (100,101). The infusion of parental thymocytes into an irradiated 
F^ recipient of parental BMC has been shown to increase the number of 
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CFU-S (29), probably secondary to improved seeding efficiency of BMC, 
into the spleen (102), as well as induce an increase in the size of 
CFU-S’s (30). In other experiments, thymocytes caused a shift in the 
erythroidrmyeloid ratio towards increased myeloid colonies (31,32,103), 
while in one particularly complex experiment, the presence of host T 
cells appeared to be required for the generation of CFU-S (32). Despite 
such evidence for thymocyte influence in the CFU-S assay, a role for 
an endogenous Thy-1+ BMC in CFU-S expression has not previously been 
demonstrated. 
In other models of hematopoiesis, T cells have been shown to augment 
erythropoiesis (33,104) and neonatal thymectomy in opossums has been 
noted to result in maturational arrest in the erythroid cell line (105). 
By examining colony forming units grown in in vitro agar cultures 
(CFU-C), a family of glycoproteins necessary for culture, called colony 
stimulating factors or activities (CSF, CSA), has been discovered. These 
CSF's are usually derived from T lymphocytes (106), unfractionated spleen 
cells (107,108,109) or miscellaneous tissues (94,110), but their genera¬ 
tion appears to be T cell dependent regardless of the tissue being used 
for production (106,109). Despite the fact that CFU-C are predominantely 
myeloid and quite different from CFU-S, it is of some interest that CSF 
has been reported to have unusual effects upon CBA/H-derived CFU-C. In 
CBA/H mice, not only do their CFU-C contain an uncommonly large erythroid 
component (109,111), but their BMC are much more sensitive to the trophic 
effects of CSF than other mice (111). In light of the heightened contra- 
suppressive characteristics of CBA/H mice, these observations are con¬ 
sistent with the concept of a role for contrasuppression in the regulation 
•A 
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of differentiation of hematopoietic stem cells. 
In another intensively studied system, the genetically transmitted 
anemia seen in W/WV mice has been shown to be amenable to cure by the 
adoptive transfer of normal BM with a source of donor T cells (either 
the untreated normal BM or normal thymocytes) (112,113). It is not 
clear how this relates to T cell influence over CFUS expression, since 
these reports maintain that the number of CFU-S is not altered by anti¬ 
theta + complement treatment of BMC, while one (112) shows that such 
treatment of BMC actually increases the proportion of myeloid colonies - 
opposite of what would be expected based on other observations (31, 
32,103). These data have been interpreted as demonstrating the exis¬ 
tence of a stem-cell independent, theta-sensitive regulatory cell (TRSC) 
that regulates stem cell differentiation (112,113). 
Similar conclusions have been advanced concerning thymocyte in¬ 
fluence on endogenous CFU-S in sublethally irradiated mice (114) and the 
role of rabbit anti-mouse brain (RAMB) antiserum in the removal of CFU-S 
activity from BMC (115). This last observation is particularly inter¬ 
esting, as Poverenny, e_t al, based their conclusions upon their ability 
to partially restore CFU-S after RAMB treatment by injecting semi- 
syngeneic thymocytes, syngeneic thymocytes, or thymosin Fraction V into 
the host. In the absence of absorption specificity controls for the 
RAMB, as was provided by Golub in his original report (116), the data 
could also be explained by another property of the RAMB, that being the 
endogenous anti-contrasuppressor activity found in rabbit serum. Lastly, 
Tyan (117) presents data that he interprets as giving evidence for a 
somewhat elaborate regulation of CFU-S proliferation. In addition to the 
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use of a rather contrived experimental design involving immunization of 
donor mice against SRBC, Tyan fails to use the appropriate complement 
controls those experiments in which BMC are treated with anti-Ly anti¬ 
sera plus RC. In those experiments, Tyan used a GPC control, a clearly 
inappropriate maneuver in light of the data presented here. 
If contrasuppressor regulation of CFU-S is to be hypothesized, it 
was necessary to first demonstrate the existence of suppressive control 
of CFU-S expression. Table 20 deals with this question by examining the 
effect of adding RC-treated BMC - to normal BCM. In both experiments, 
such a mixture resulted in decreased CFU-S compared to untreated BMC. 
Although the small number of mice used in these experiments precludes 
any firm conclusions from being drawn, it did appear that RC treatment 
of BMC unmasked a suppressive activity directed at CFU-S expression. 
These experiments also indicate that the CFU-S reducing activity of RC 
is not primarily due to an anti-stem cell activity, although minor 
losses of stem cells cannot be ruled out. Consequently, the RC activity 
can be said to be directed against a cell that reduces suppression, a 
contrasuppressor possibily analogous to Poverenny’s CFU-S accessory 
cell (115), in the CFU-S assay system. 
In all the experiments discussed, the perceived connection between 
the iri vitro culture and CFU-S assay systems was based upon data derived 
from manipulations that gave predictable in vitro results with which 
CFU-S assay results could be compared. Figure 5 turns this process 
around to demonstrate that physiologic stressing of BM hematopoiesis 
can result in alterations of the in vitro culture characteristics of 
BMC. In these experiments, the BM of anemic mice was much less suppres- 
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sive than that of control mice. This decrease in suppression could not 
be attributed to dilution of the BMSC by proliferating hematopoietic 
cells and, furthermore, suppression was restored towards control levels 
by depleting the anemic BM of Thy-1+ cells. Previous work has found 
that anemic mice generate more transferable CFU-S in their BM (118,119) 
and WS (120,121), and they possess more endogenous CFU-S (120). This is 
probably a consequence of selectively stressing the erythroid cell line, 
as bled mice demonstrate increased erythropoietic proliferation (122) 
and a decreased number of non-erythroid CFU-S (123), while polycythemia 
results in a decreased number of CFU-S with an increased proportion of 
non-erythroid CFU-S (123,124). Thus, the data presented here indicates 
that by stressing BM hematopoiesis in such a way as to increase CFU-S 
expression, a parallel decrease in in vitro BM suppression is also 
produced, apparently via increased contrasuppression. At this point, 
having seen that perterbations in contrasuppression in either experi¬ 
mental system result in parallel changes in the other, and given the 
phenotypic correspondence between the contrasuppressors in either system, 
it is not unreasonable to hypothesize that the two contrasuppressors are 
very closely related cells, perhaps even identical. 
There is one piece of data that seemingly contradicts the above 
discussion, however. In Table 21, two different experiments utilizing 
three separate experimental groupings clearly show that neonatal BMC 
generates significantly fewer CFU-S than adult control BMC. Given the neo¬ 
nate's severe hematopoietic stress and well-documented high level of 
contrasuppression, this data obscures the relationship between CFU-S, 
physiologic hematopoiesis, and contrasuppression. This might be explained 
by the presence of an artifactual factor in the CFU-S assay; however. It 
. 
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is easily appreciated that the initial controlling event in CFU-S gen¬ 
eration is the lodging of the stem cell in the recipient spleen. The 
seeding efficiency, the percentage of stem cells successfully lodging 
in the spleen, has been estimated to be 10-15% under normal conditions 
(31,125). This figure, though, has been shown to be sensitive to the 
proliferative activity of the cells used. In particular, during fetal 
and neonatal life, hematopoietic cells have extremely short cycling 
times (122,125), a condition that is associated with a seeding efficiency 
only 1/3 to 1/2 of normal (125). It is quite likely, then, that the 
reduced CFU-S seen with neonatal BMC is due to an artifact of the CFU-S 
assay rather than to a lack of contrasuppressive influence over hema¬ 
topoiesis. 
If the Thy-1+ contrasuppressor is, in fact, a significant factor 
in the control of in vivo hematopoiesis, it might then be possible to 
link some clinical hematological disorders to derrangements in suppressor 
contrasuppressor balance. Of particular relevance are the numerous 
studies of various types of BM failure resulting in anemia, neutropenia, 
or pancytopenia. In Diamond-Blackfan Syndrome, the pure red cell hypo¬ 
plasia has been associated by some investigators to lymphocytic suppres¬ 
sion of BM (126), but this view is not unanamous (127,128). Acquired 
red cell aplasia can sometimes be ascribed to circulating autoantibodies 
(129), but good evidence for a cell mediated immunologic dysfunction is 
lacking (128). In neutropenia associated with collagen vascular diseases 
particularly Felty’s syndrome, it has been observed that suppression of 
myeloid CFU-C is T lymphocyte dependent (130,131). In isolated neutro¬ 
penia, there appears to be a non-T mononuclear cell in BM and peripheral 
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blood that also suppresses CFU-C expression (132,133). Comparable 
studies of aplastic anemia have shown that up to 50% of patients have 
a mononuclear cell (134) or non-T lymphocyte (135) mediated suppression 
of CFU-C. Interesting, in one report (136), a 12 hour in vitro pre¬ 
culture of the patient's BM greatly augmented its suppressive capability, 
a phenomenon that has been noted with murine BMC (63,64). From another 
perspective, the role of contrasuppression in the emergence of hema¬ 
tological neoplasms is a totally unexplored, though intriguing, area 
of inquiry. On the whole, however, although the literature gives a 
few tantalizing hints of inappropriate BMSC function in certain disease 
states, notably isolated neutropenia and some aplastic anemias, no firm 
conclusions can yet be drawn based on the evidence available. 
IV. The regulation of bone metabolism 
A guiding principle in the evaluation of the BM contrasuppressor 
was that its microenvironment was an important determinant of its 
function. Given its intimate association with bone, a few exploratory 
experiments were undertaken in an effort to uncover contrasuppressor 
activity that pertained to bone metabolism. 
Normal bone metabolism can be viewed on a cellular level as a 
dynamic equilibrium in which "the events of formation and resorption are 
not random, but coupled. Formation follows resorption and takes place 
at sites of previous resorption" (137). In this interplay, the role of 
bone resorption is ascribed to the osteoclast (138), a multinucleated 
cell that has been shown to derive from blood-borne cells (34,139,140, 
141,142), possibly mononuclear phagocytes (138,143). Under normal cir¬ 
cumstances, the controlling determinant of the level of resorptive 
activity is parathyroid hormone (PTH), secreted by the parathyroid 
- 
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glands. PTH increases bone resorption by increasing the activity of 
existing osteoclasts (138,144) while simultaneously generating an in¬ 
crease in osteoclast numbers by recruitment of blood-borne cells 
(138,145,146). Interestingly, neither an osteoclast PTH-receptor nor 
evidence for a direct effect upon monocytes by PTH has yet been dis¬ 
covered, although other bone marrow cells have been shown to possess 
PTH-receptors (138). This has led to the suggestion that PTH induces 
local regulatory changes in bone that result in greater monocyte trap¬ 
ping and osteoclast activation (138). 
With this in mind, the experiments in Figures 6 and 7, which were 
designed to examine the _in vitro effects of PTH upon BMC, show that the 
brief exposure of BMC to PTH prior to in vitro culture resulted in signif¬ 
icantly less BM suppression. This implies that the level of contrasup- 
pression was increased, although whether this reflects changes in sup¬ 
pression or contrasuppression cannot be discerned from these experiments. 
It is unlikely that this PTH effect was simply due to dilution of the 
BMSC by proliferation of unrelated PTH-responsive cells since the PTH 
exposure time of 3.5 hours was probably too brief to allow significant 
proliferation compared to the control pre-incubation. Figure 7 supports 
this contention, in that the divergent slopes of the dose response 
curves for normal and PTH-treated BMC suppression implies that different 
cellular interactions were occurring in the two situations. If it were 
only a matter of BMSC dilution, the curves would be parallel. Thus, 
either the BMSC or BM contrasuppressor possesses a function PTH-receptor, 
the activation of which alters the balance between suppression and 
contrasuppression as detected in an in vitro antibody production assay. 
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Why an overlap of such disparate biological systems appears to be 
occurring will be discussed later. 
With respect to lymphocyte mediation of bone resorption, much 
interest has been focused upon the actions of a peculiar lympho- 
kine called osteoclast activating factor (OAF). This lymphokine is 
produced by activated lymphocytes (138,147), in association with mono¬ 
cytes that secrete prostaglandin (147,148), and has been implicated 
as the etiology of the osteolytic lesions seen in multiple myeloma 
(36,149) and T cell lymphoma (35). Although not completely understood, 
the biochemical mechanism of action of OAF appears to be different 
from that of PTH, as indicated by the requirement for an intact pros¬ 
taglandin pathway for OAF, but not PTH, activity (36,147,148). It is 
unlikely, though, that the BM contrasuppression phenomenon is prosta¬ 
glandin mediated since concentrations of PTH up to 100 times that used 
in these experiments, when used to stimulate in vitro bone resorption, 
do not give rise to increased prostaglandin synthesis (148). 
One experimental model of cellular regulation of bone metabolism 
has been osteopetrotic rodents that have genetically determined myelo¬ 
fibrosis of the marrow cavity apparent at birth or shortly thereafter. 
The best known of these animals, the micropthalmic (mi/mi) mouse, has 
been fruitfully investigated by Walker (139,150,151) and others (141), 
who have been able to cure the osteopetrotic defect by the adoptive 
transfer of normal BM or spleen cells to the mi/mi mice. Conversely, 
the transfer of mi/mi spleen cells to lethally irradiated normal litter- 
mates resulted in osteopetrotic recipient mice (141,150). Although the 
osteopetrotic defect is not T cell in nature, these experiments confirm 
the cellular nature of the dysfunction. Perhaps more germaine to the 
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discussion, this data indicates that under these conditions, the cells 
regulating bone metabolism migrate to the spleen where, it will be 
recalled, extramedullary hematopoiesis and a Thy-1 suppressor cell are 
also found following marrow cavity obliteration (64,67). 
Although the data presented here do not conclusively show that PTH 
increases contrasuppressor (i.e. Thy-1+, RC sensitive) activity, other 
circumstantial evidence indicates that a Thy-1+ may be involved in the 
regulation of bone resorption. In a rat model of osteopetrosis, the 
op/op rat, infantile osteopetrosis was correctable by transplantation of 
a thymus from a normal littermate (34). In addition, athymic nude mice, 
who have histologically normal bone structure (34), have been reported 
to have a much lower bone turnover rate than normal mice (152). 
V. The BM contrasuppressor as co-ordinator of BM functions 
If it is assumed that the BM contrasuppressor participates in both 
bone metabolism and hematopoiesis, then it might be possible that these 
two physiological systems directly interact, especially given their 
observed co-migration under certain circumstances. A recent report 
indicates that, at least under extreme physiologic stress, hematopoietic 
regulatory mechanisms may alter bone metabolism. 
It is widely taught that thalassemia major is associated with dis¬ 
tinctive skeletal abnormalities. Pootrakul at al (153), found that 
patients who were severely anemic secondary to thalassemia major also 
had histologic bone abnormalities consisting of osteopenia and decreased 
mineralization associated with increased bone turnover and low PTH 
levels. After simply transfusing these patients to relieve their anemia, 
the investigators found decreased BM turnover associated with histologic 
bone changes indicating reduced osteoclastic activity and lower bone 
turnover, accompanied by an increase in serum PTH. This succession of 
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events is what would be predicted by a regulatory model involving some 
degree of interaction between hematopoiesis and bone metabolism, although 
other explanations of these events are certainly possible. It could be 
argued, though, that there is a physiologic incentive for such an inter¬ 
action, since this mechanism of altering bone metabolism would permit a 
large marrow expansion under conditions of extreme hematopoietic stress. 
The local nature of this interaction is revealed by the fact that PTH 
levels were inversely related to bone resorption activity, implying that 
parathyroid gland activity was a reaction to, rather than a cause of, 
the high level of osteoclastic activity. Cross-reacting cellular inter¬ 
actions involving contrasuppression in the two relevant physiologic 
systems would certainly be consistent with this scenario. 
If it is to be accepted that the BMSC and the BM contrasuppressor 
play a role in the regulation of hematopoiesis and bone metabolism, it 
remains to be explained why these cells can be detected in an in vitro 
immunological assay. Marluzzi (64) observed that the Thy-1 splenic 
89 
suppressor cell found in Sr treated mice was capable of suppressing 
in vivo PFC's only if the spleen cells were first passed through a 24 hr 
in vitro culture before transfer into the host mouse. This suggests 
that a selective differentiation occurs under in vitro conditions which 
leads to amplification of an immunologically suppressive cell. By 
extrapolation, it may be worthwhile to view the BMSC as not one cell 
but several closely related cells, perhaps arising from a common pre¬ 
cursor cell which generates specific suppressors in accordance with the 
immediate physiologic stresses. Conversely, there may be a common BMSC 
whose activity within each physiologic sphere is regulated by one of an 
array of closely related Thy-1+ contrasuppressors. While such arrange- 
- 
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merits would help to account for the Inter-system Interactions, it is 
obvious that the specific cells being examined would be a function of 
the experimental design employed. Further dissection of this concept 
will require much more extensive phenotypic investigation of the BMSC 
and BM contrasuppressor. 
On a slightly more abstract level, this thesis represents the 
first report of contrasuppression in either the bone marrow or in a 
physiologic system free of exogenous influences. This cell, probably 
-f- 
a lymphocyte, is Thy-1 but in the absence of proof of thymic depen¬ 
dence, it may be premature to call it a T cell (58,154,155). To the 
limited extent that it has been characterized, this cell is similar 
to the contrasuppressor found in an immunological assay involving neo¬ 
natal spleen cells (15,16,41). In that experimental system there is 
a Thy-1+, Ly-1+, I-J+ cell that acts to render T helper cells resis¬ 
tant to suppression by Ly-2+ cells. In addition to a hypothetical 
global function for the contrasuppressor, such as in the hyperimmune 
state and in the transfer of delayed-type hypersensitivity, it has 
been suggested that contrasuppression may help regulate highly localized 
humoral immune responses (16). While this is probably not the case 
with the BM contrasuppressor, for the reasons discussed earlier in 
connection with BM antibody production, by expanding the domain of con¬ 
sideration to include hematopoiesis and bone metabolism it might be 
fair to view the BM contrasuppressor as a major determinant of the 
response to and control of micro-environmental changes. 
As such, the greater significance of the BM contrasuppressor re¬ 
lates not to the specifies of its activities within each of its domains 
but, rather, to the light it sheds upon the interactions between 
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physiologic systems previously considered independent of one another. 
A multi-system physiologic response to various forms of stress is now 
a widely acknowledged paradigm, but without a greater understanding 
of this process on a cellular level rational attempts at medical inter¬ 
vention are impossible. This thesis sketches an integrated bone marrow 
physiology in which perturbations in local immune functions, hemato¬ 




In the basic feedback suppressor circuit, the cellular interactions 
can be diagramed as follows: 
H 
antigen 






While such a representation ignores the details of the recruitment of 
lymphocytes from the pool of precursor lymphocytes, it is sufficient to 
display the major components of the feedback circuit. In simplest form, 
antigen (Ag) triggers T helper cells (Lyl) to aid in the production of 
antibody by delivering help (H) to B cells while a subpopulation of Lyl 
cells simultaneously triggers suppressor cells (T ) which act to lessen 
the antigen responsiveness of T helper cells. Straightforward analysis 
of this feedback loop (156) yields the equation 
where H = help delivered 
Ag = antigen 
Lyl - T helper cell function 
T = T suppressor cell 
function. 
Thus, for given cellular response characteristics, it is possible to 
define the help delivered as a function of the antigen stimulus. 
The concept of a contrasuppressor cell adds complexity to the 
system, but it too can be readily evaluated through similar block 
diagram analysis. Assuming that the contrasuppressor (CS) interacts 
within the Lyl - Tg domain, four different circuit possiblities can 
be envisioned. That is, the contrasuppressor can be stimulated by either 




the Lyl or Tg cell and it could act upon either cell. These four 
basic circuits can be seen in Figure A, with the stimulant and acted- 
upon cells (with respect to the contrasuppressor cell) noted for each 
circuit. 
On a theoretical basis, there is no cause to favor any one of the 
circuits described. However, experimental evidence (16) indicates that 
the contrasuppressor requires the presence of suppressor cells to be 
activated and that it acts to make T helper cells insensitive to 
suppression. These results are best accounted for by model IV in 
Figure A, although it is most definitely a very simplified representation 
of the cellular events involved. 
By analyzing model IV, a mathematical representation can be 
derived as before: 
H = Ag( 
_Lyl_ 
1 + (Lyl)(T - CS) 
s 
where CS = contrasuppressor 
cell function. 
Ignoring the kinetics of the situation for a moment, it can be seen 
that as contrasuppression increases, between 0 and T , the denominator 
s 
independently decreases, thereby increasing the magnitude of H (help) 
delivered by the circuit. The contrasuppressor, then, can be viewed as 
a fine-tuning gain control for the circuit as a whole. It can also be 
appreciated that, depending upon the particular kinetics of the cells 
involved, the contrasuppressor can also increase the responsiveness of 
the circuit and thereby allow a quick antibody response to the sudden 
introduction of an antigen that has been previously encountered. A 
more detailed exploration of this concept would be best accomplished 
through the use of an analogue computer. 
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Adapted from: Genealogies of Long-Separated Sublines in Six 
Major Inbred Mouse Strains; in Inbred and Genetically Defined 
Strains of Laboratory Animals. Part 1. Mouse and Rat. (P.L. 
Altman and D.D. Katz, eds.); Fed. Amer. Soc. Exp. Biol., Bethesda, 
Md,1978; p. 19. 
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